Abstract
SummaryDry eye syndrome is a chronic disease that affects tens of millions of people worldwide, representing one of the most common ocular pathologies. The traditional approach to treat dry eye focuses on tear replacement with artificial tears or on conserving the patients’ tears through occlusion of the tear drainage system, but these therapies can be considered palliative in that they do not address the pathogenic process that underlines the disease. This presentation will discuss the recent major advances in managing dry eye patients, including a new algorithm of therapy and new technologies that can help in monitoring the effect of treatments, and the results of studies with new molecules‐ ocular surface modulators‐ aimed at restore the tear film‐ocular surface epithelia equilibrium.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call